A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC

Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jaejun, Sung, Pil Soo, Yang, Hyun, Lee, Soon Kyu, Nam, Hee Chul, Yoo, Sun Hong, Lee, Hae Lim, Kim, Hee Yeon, Lee, Sung Won, Kwon, Jung Hyun, Jang, Jeong Won, Kim, Chang Wook, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767204/
https://www.ncbi.nlm.nih.gov/pubmed/33371271
http://dx.doi.org/10.3390/jcm9124121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767204/
https://www.ncbi.nlm.nih.gov/pubmed/33371271
http://dx.doi.org/10.3390/jcm9124121

Ejemplares similares